Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.

Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K.

PLoS One. 2011;6(9):e24739. doi: 10.1371/journal.pone.0024739. Epub 2011 Sep 12.

2.

Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.

Björkelund H, Gedda L, Andersson K.

PLoS One. 2011 Jan 31;6(1):e16536. doi: 10.1371/journal.pone.0016536.

3.

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.

He P, Li G.

Cancer Chemother Pharmacol. 2013 Aug;72(2):341-8. doi: 10.1007/s00280-013-2198-6. Epub 2013 Jun 8.

4.

Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.

Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J.

Cancer Lett. 2009 Oct 8;283(2):135-42. doi: 10.1016/j.canlet.2009.03.034. Epub 2009 Apr 19.

PMID:
19380191
5.
6.

Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.

Favoni RE, Pattarozzi A, Lo Casto M, Barbieri F, Gatti M, Paleari L, Bajetto A, Porcile C, Gaudino G, Mutti L, Corte G, Florio T.

Curr Cancer Drug Targets. 2010 Mar;10(2):176-91.

PMID:
20088784
7.

Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

Meco D, Servidei T, Riccardi A, Ferlini C, Cusano G, Zannoni GF, Giangaspero F, Riccardi R.

Neuro Oncol. 2009 Jun;11(3):250-9. doi: 10.1215/15228517-2008-095. Epub 2008 Nov 25.

8.
9.
11.

Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.

Lin HQ, Katsifis A, Meriaty H.

Anticancer Res. 2010 Dec;30(12):4899-905.

PMID:
21187468
12.

Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.

Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.

Cytometry A. 2011 Sep;79(9):684-93. doi: 10.1002/cyto.a.21107. Epub 2011 Jul 22.

14.

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.

Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM, Vallis KA.

J Nucl Med. 2007 Sep;48(9):1562-70. Epub 2007 Aug 17.

15.

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.

Int J Cancer. 2008 Dec 15;123(12):2939-49. doi: 10.1002/ijc.23902.

16.
17.

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.

Nutt JE, Foster PA, Mellon JK, Lunec J.

Br J Cancer. 2007 Mar 12;96(5):762-8. Epub 2007 Feb 20.

18.

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR.

Breast Cancer Res Treat. 2008 Sep;111(1):79-91. Epub 2007 Sep 28.

PMID:
17902048
20.

Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.

Björkelund H, Gedda L, Malmqvist M, Andersson K.

Mol Clin Oncol. 2013 Mar;1(2):343-352. Epub 2012 Oct 30.

Supplemental Content

Support Center